Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Cambium Oncology LLC is managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This case is assigned to examiner LINDSAY MICHELLE DUNN, who is the distinct examiner and the distinct art unit involved in the company's current filings.
LINDSAY MICHELLE DUNN is the busiest examiner with 1 pending office action. Because the company has the distinct art unit active, the prosecution strategy is dependent on the technical review and feedback provided by the examiner in the biotechnology sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DUNN, LINDSAY MICHELLE | 1 | 80.0% | +0.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18562111 | VASOACTIVE INTESTINAL PEPTIDE (VIP) RECEPTOR ANTAGONISTS | DUNN, LINDSAY MICHELLE | — |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18562111 | VASOACTIVE INTESTINAL PEPTIDE (VIP) RECEPTOR ANTAGONISTS | DUNN, LINDSAY MICHELLE | 1644 | §102§112DP | Non-Final OA | — | Pending | Nov 17, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCambium Oncology LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Lindsay Michelle Dunn has the most, with 1 of Cambium Oncology LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
